



CHLORASOLV CE APPROVAL GRANTED

BTC health (ASX: BTC) announced today that ChloraSolv wound care product, licensed from RLS Global AB in Sweden, has received CE approval. ChloraSolv is licensed to BioImpact Pty Ltd, a wholly owned subsidiary of BTC health.

CE approval is a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area.

CE approval is an important step towards the commercialisation of ChloraSolv in Australia and New Zealand. BTC expects that ChloraSolv will be available in Australia/ New Zealand during 2020.

ChloraSolv is a topical gel which is classified as a medical device. It is clinically proven to effectively clean and assist with the healing of chronic wounds. The method of treatment is simple and safe and shortens each treatment session and the time it takes for slow-healing wounds to heal. It represents a unique and modern approach to the effective treatment of hard-to-heal diabetic ulcers, venous stasis ulcers and pressure sores.

For more information please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@btchealth.com
+61 417 520 509

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.